Serine/threonine kinase 17B (STK17B), also known as DAP kinase-related apoptosis-inducing protein kinase 2 (DRAK2), is a member of the DAPK family which has emerged as a potential cancer immunotherapy target. This evidence concerns the gene STK17B and cancer.